Detalhe da pesquisa
1.
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
BMC Cancer;
18(1): 106, 2018 01 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29382302
2.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol;
13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22285168
3.
Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03).
Ther Adv Med Oncol;
13: 17588359211022905, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34349841
4.
[Prognostic value of ERBB2 amplification and protein expression in small cell lung cancer]. / Valor pronóstico de la expresión y amplificación genética de c-erbB-2 en el carcinoma microcítico de pulmón.
Arch Bronconeumol;
44(3): 122-6, 2008 Mar.
Artigo
em Espanhol
| MEDLINE
| ID: mdl-18361882
5.
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
JAMA Oncol;
1(2): 149-57, 2015 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26181014
6.
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Clin Lung Cancer;
5(6): 360-5, 2004 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15217535
7.
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Lung Cancer;
81(1): 84-90, 2013 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23611405
8.
Cisplatin plus oral vinorelbine as first-line treatment for advanced non-small-cell lung cancer: a prospective study confirming that the day-8 hemogram is unnecessary.
Clin Transl Oncol;
15(8): 659-64, 2013 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23359178